NewsSource: EClinCloud official website historical archive

Committed to Serving Global Clinical Research: Microsoft Supports EClinCloud's Accelerated Global Expansion

6 min readEClinCloud Editorial Team
Archived article cover: Committed to serving global clinical research, Microsoft supports EClinCloud's accelerated global expansion

The following article is sourced from Microsoft Partner Ecosystem, by Microsoft Partner Ecosystem

In 2015, drug review reform began, and innovation in China's pharmaceutical industry experienced explosive growth. With steadily increasing R&D investment, innovative drug pipelines began to expand rapidly and the number of new drugs reaching the market continued to grow. Studies show that over the past 10 years (2010–2020), both Investigational New Drug (IND) applications and New Drug Applications (NDAs) in China achieved rapid growth. However, the key metric of “ duration of the clinical trial phase ” extended from 2572 days to 2688 days. This upward rather than downward trend has made improving clinical trial efficiency one of the most pressing pain points to address in current new drug innovation. Guided by its core mission centered on digital tools and grounded in science and medicine to support clinical R&D for new drugs and medical devices, EClinCloud was established.



A New Entrant in the Healthcare Sector

Also a leader in industry development

 

The founding of EClinCloud landed squarely on industry pain points and stepped into the trend's "sweet spot."

 

Clinical trials are widely recognized as the most costly, time-consuming, and critical stage before a new drug reaches the market. Improving the efficiency of drug clinical trials and collecting, organizing, and validating clinical trial data in a scientific, accurate, and compliant manner is a shared goal for pharmaceutical R&D professionals. The COVID-19 outbreak made these challenges even more pronounced. EClinCloud was founded at a pivotal juncture for the industry, entering the clinical research sector with an integrated clinical trial SaaS cloud platform solution as its core driver. To date, a large number of clients have conducted domestic and international clinical trials on EClinCloud's digital system.

 

一临云临床试验一站式数字化解决方案介绍  

 

EClinCloud, positioned as an integrated clinical evidence support SaaS cloud platform, has established collaborations with multiple innovative pharmaceutical companies and CROs in China and abroad. With the support of international experts, EClinCloud has successfully expanded its business in scale management, rater training, backend medical support, and endpoint assessment for multicenter clinical trials and related areas. In digital clinical research operations, EClinCloud has accumulated ample capabilities and project experience.

 

 

To do good work

See EClinCloud's "Full Arsenal of Capabilities"

 

Guided by the mission of "bringing effective treatments to patients through technological innovation," and based in China while serving global healthcare and life sciences enterprises, EClinCloud has a core team with an average of over 16 years of industry experience. They deeply understand that in clinical trial digitalization, IT is a tool, whereas understanding clinical protocols and clinical operations from medical and scientific perspectives is the foundation for truly identifying client needs and resolving industry pain points. Deeply rooted in the industry for many years and strongly recognized by clients, EClinCloud offers products and services that are undoubtedly their most powerful weapon.

 

一临云治疗领域、专业团队与技术能力介绍  

 

First and foremost is a therapeutic-area-focused, one-stop clinical endpoint assessment solution. This solution helps standardize clinical trial endpoint data and improve data credibility and reliability, thereby increasing the success rate of bringing drugs to market. The solution primarily includes scale management, rater training, the eCOA system, central reading, and more.

 

The integrated clinical trial SaaS cloud platform released in July this year is EClinCloud's second major weapon. EClinCloud's integrated clinical trial cloud platform establishes unified data standards and, built on a unified underlying architecture and a SaaS cloud platform, achieves data interoperability across its systems. EClinCloud's integrated cloud platform comprises six stable, reliable, and streamlined systems, each with its own core strengths: a clinical trial management system (CTMS), an electronic trial master file management system (eTMF), an electronic clinical outcome assessment system (eCOA), an electronic data capture system (EDC), a randomization and trial supply management system (RTSM), and a resource management system (RM). The interoperability across EClinCloud's systems addresses the problem of information silos currently faced by many companies, improves R&D efficiency and reduces R&D costs, and can bring substantial value to customers.

 

一临云治疗领域、专业服务与系统产品一览  

 

Moreover, supported by the integrated application of cutting-edge digital technologies such as big data, artificial intelligence, and cloud computing, EClinCloud applies an innovative "Technology + Data + Industry" model to develop intelligent tools that enable the digital transformation of clinical trials, which will reduce labor and time costs in clinical trials to a greater extent and improve efficiency.

 

皮肤病生活质量问卷移动端界面示例  

The EClinCloud team has a global perspective and serves domestic enterprises to international standards. As its footprint has gradually deepened and the company has continued to grow and develop, EClinCloud has begun accelerating its international expansion.

 

Microsoft X EClinCloud

A Serendipitous Encounter and an Ideal Partnership

 

EClinCloud's first encounter with Microsoft began by chance. In a collaborative project with AstraZeneca, a leading global multinational pharmaceutical company, Microsoft Cloud resources provided by AstraZeneca laid the foundation for the collaboration's success, using infrastructure such as cloud servers, databases, and object storage provided by Microsoft Cloud and integrating with the  AD domain, though EClinCloud had not yet established a partnership with Microsoft Cloud at that time. As its business grew and overseas site deployments expanded, EClinCloud began seeking a cloud service partner, considering several top-ranked international providers, with Microsoft Cloud among them.

 

After extensive comparison, EClinCloud ultimately selected Microsoft Cloud as its cloud infrastructure service provider for deploying SaaS overseas. What EClinCloud valued was not only Microsoft Cloud's strong technical capabilities, but more importantly, a sound and sustainable commercial partnership for the future. The two were immediately aligned in their development philosophy.

 

Currently, EClinCloud's  Azure primary site is in the US East region. EClinCloud will make full use of the various resources and services provided by Microsoft Cloud to grow its overseas business, pursuing further exploration and application in high availability, performance, cross-border data transfer, and compliance. It hopes to use Azure to build EClinCloud's SaaS cloud platform for regions outside China, serving global clinical research.

 

使用笔记本电脑查看临床研究管理系统  

 

The digital transformation of pharmaceutical R&D has entered a new stage. The founding of EClinCloud has addressed industry pain points, and the company also faces further opportunities and challenges. In the days ahead, Microsoft Cloud and EClinCloud will continue to explore together, injecting sustained momentum and utility into the development of clinical medicine.


About EClinCloud

EClinCloud is a technology company dedicated to clinical research and development, providing an integrated, interoperable, all-in-one cloud platform for clinical trials (including CTMS, eTMF, EDC, RTSM, and eCOA, among other technology products, and scale management, linguistic validation, rater training, and data quality analysis, among other solutions), as well as clinical trial endpoint assessment technologies across different therapeutic areas (including oncology, central nervous system, and ophthalmology, among others). Combining cutting-edge technology with life data, it builds a globally leading "patient-centric" SaaS cloud platform for clinical evidence support, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the launch of drugs/devices, and benefit countless patients.

Related reading

Archived article cover: With Rising Pharmaceutical Submissions and Tightening Investment, How Can Digital Solutions Help Clinical Research Reduce Costs and Improve Efficiency?News7 min readWith Rising Drug Filings and Tightening Investment, How Can Digital Solutions Help Reduce Costs and Improve Efficiency in Clinical Research?As the biopharmaceutical industry continues to develop, innovative drug R&D has entered a period of rapid growth, and the number of clinical drug trials is trending upward. Alongside this, improving clinical trial efficiency and reducing the costs and risks of clinical research have become urgent priorities for a growing number of pharmaceutical companies and research institutions. Using digital tools to advance the digital and intelligent development of clinical trials is undeniably the prevailing trend. To better meet the needs of digital and intelligent clinical development and share the latest achievements and solutions, EClinCloud recently convened in Chengdu its first User Conference, "Digital and Intelligent Empowerment: Symbiosis and Win-Win," bringing together pharmaceutical industry leaders for discussions.Article cover for "Scale scoring: a different score from every rater? An overview of the history of neuropsychological scale assessment"News8 min readInconsistent Scale Scoring? Understanding Neuropsychological Scale AssessmentIn neurology, neuropsychological assessment is an indispensable tool in clinical diagnosis and research. However, during clinical scale assessments, raters may apply varying degrees of subjective judgment and interpret the scales inconsistently, leading to differences in scoring outcomes; if a rater uses leading language or questions during the assessment, this can also introduce bias into the results. In the field of neuropsychology in particular, neuropsychological assessment results often serve as the primary endpoint of clinical trials; biased results may reduce a clinical trial's reliability and, in severe cases, lead to study failure. Therefore, standardized training on the use of neuropsychological assessment scales is necessary to...Archived article cover: EClinCloud eCOA system passes CFDI inspection, supporting marketing approval of Raynovent's COVID-19 treatment leritrelvir tabletsNews4 min readEClinCloud eCOA System Passes CFDI Inspection, Supporting Marketing Approval of Raynovent's COVID-19 Treatment Leritrelvir TabletsOn March 23, 2023, in accordance with the relevant provisions of the Drug Administration Law and under the special drug approval procedures, the National Medical Products Administration (NMPA) granted conditional marketing approval to leritrelvir tablets (brand name: Leruiling), a Category 1 innovative drug submitted by Guangdong Raynovent Biotech Co., Ltd. (hereinafter referred to as "Raynovent"). The drug is an oral small-molecule therapy for novel coronavirus infection, indicated for the treatment of adult patients with mild-to-moderate novel coronavirus infection (COVID-19).